CDT Equity (CDT) Return on Capital Employed (2022 - 2026)
CDT Equity's (CDT) quarterly Return on Capital Employed came in at 82.36% in Q1 2026, down 102629.0% YoY from N/an in Q1 2025, and down 112.8% on a QoQ basis from 643.47% in Q4 2025.
CDT Equity (CDT) Return on Capital Employed (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has 5 years of Return on Capital Employed data on file, last reported at 82.36% in Q1 2026.
- Quarterly Return on Capital Employed fell 102629.0% year-over-year to 82.36% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 82.36% (down 102629.0% YoY) and the FY2025 annual result came in at 465.91%, up 15990.0% from the prior year.
- Return on Capital Employed slipped to 82.36% in Q1 2026, from 643.47% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 943.93% in Q1 2025 to a low of 2509.2% in Q3 2025.
- A 5-year average of 45.09% and a median of 181.06% in 2024 frame the typical range for Return on Capital Employed.
- The widest YoY moves for Return on Capital Employed: up 53812 bps in 2025, down 267158 bps in 2025.
- Tracing CDT's Return on Capital Employed over 5 years: stood at 4.9% in 2022, then tumbled by 1272 bps to 67.29% in 2023, then surged by 420 bps to 215.44% in 2024, then soared by 199 bps to 643.47% in 2025, then plunged by 113 bps to 82.36% in 2026.
- The last three Return on Capital Employed figures came in at 82.36% (Q1 2026), 643.47% (Q4 2025), and 2509.2% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | -33.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -33.74% |
| Mar 31, 2026 | -82.36% |
| Dec 31, 2025 | 643.47% |
| Sep 30, 2025 | -2,509.20% |
| Jun 30, 2025 | 613.56% |
| Mar 31, 2025 | 943.93% |
| Dec 31, 2024 | 215.44% |
| Sep 30, 2024 | 162.38% |
| Jun 30, 2024 | 199.73% |
| Mar 31, 2024 | 405.81% |
| Dec 31, 2023 | -67.29% |
| Sep 30, 2023 | -242.83% |
| Jun 30, 2023 | 94.89% |
| Mar 31, 2023 | 258.57% |
| Dec 31, 2022 | -4.90% |